



Correction to *Lancet Neurol* 2022; 21: 42–52

Mercuri E, Deconinck N, Mazzone ES, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. *Lancet Neurol* 2022; 21: 42–52—For this Article, the SUNFISH Study Group has been updated, and the appendix has been corrected. These corrections have been made to the online version as of April 13, 2022.

Correction to *Lancet Neurol* 2022; 21: 329–41

Morenas-Rodríguez E, Li Y, Nuscher B, et al. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. *Lancet Neurol* 2022; 21: 329–41—In this Article, the Copyright should read "© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license". In Figure 5, the y-axis of panel 5E should be "Rate of cognitive change (z-score per year)" and the x-axis under panel 5F should be "Estimated years to symptom onset". These corrections have been made to the online version as of April 13, 2022.